CoChat

Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study

Open access
Tanaka, Ryota, Yamashiro, Kazuo, Okuma, Yasuyuki, Shimura, Hideki, Nakamura, Shinichiro, Ueno, Yuji, Tanaka, Yasutaka, Miyamoto, Nobukazu, Tomizawa, Yuji, Nakahara, Toshiki, Furukawa, Yoshiaki, Watada, Hirotaka, Kawamori, Ryuzo, Hattori, Nobutaka, Urabe, Takao · 2015 · Journal of Atherosclerosis and Thrombosis
Cited by 56

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

AIM: Prediabetes is an independent risk factor for future stroke. However, no effective treatment has yet been established for the recurrence of stroke in patients with prediabetes. Here we investigated the effects of pioglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist, for the reduction of recurrent stroke in patients with prediabetes. METHODS: Participants were patients who had a symptomatic ischemic stroke or transient ischemic attack (TIA) without a history of type 2 diabetes mellitus and who were diagnosed to have IGT or newly diagnosed diabetes by a 75-g oral glucose tolerance test. These patients were randomized to either receive or not receive pioglitazone. The primary endpoint was a recurrence of ischemic stroke. RESULTS: A total of 120 patients were enrolled in the study. Sixty-three patients received pioglitazone and 57 were enrolled in the control group that did not receive pioglitazone. The majority of patients (68.3%) were prescribed 15 mg of pioglitazone, while the remaining patients (31.7%) were treated with 30 mg of pioglitazone. Over a median follow-up period of 2.8 years, treatment with pioglitazone was found to be associated with a lower rate of the primary endpoint (recurrence of stroke) than that observed in the control group [event rate=4.8% pioglitazone vs 10.5% control, hazard ratio=0.62, 95% confidence interval 0.13-2.35, p=0.49]. However, differences were not statistically significant. CONCLUSIONS: While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5551/jat.30007

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 56

Metadata

Authors
Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., Furukawa, Y., Watada, H., Kawamori, R., Hattori, N., & Urabe, T.
Venue
Journal of Atherosclerosis and Thrombosis
Published
2015
Volume
22
Issue
12
Pages
1305-1316
ISSN
  • 1340-3478 (ISSN-L)
  • 1880-3873
OpenAlex
W1128528964
Cited by
56
References
10
FWCI
5.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. https://app.cochat.ai/papers/10.5551/jat.30007
The paper
Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., Furukawa, Y., Watada, H., Kawamori, R., Hattori, N., & Urabe, T. (2015). Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.30007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.